Drugs / ARU-1801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02186418 | Jul 2014 → Oct 2022 | sickle cell disease | Children's Hospital Medical Center, Cincinnati | Terminated | Met primary Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-21 | Jasper Therapeutics, Inc. | Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease jaspertherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARU-1801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02186418 ↗ |
| Route | Intravenous | “Administered via IV infusion.” NCT02186418 ↗ |